
- /
- Supported exchanges
- / US
- / HYPMY.PINK
Hypera SA (HYPMY PINK) stock market data APIs
Hypera SA Financial Data Overview
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamma, Mioflex " A, Nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, Softalm, Tacroz, Tinodin, Umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, Equilibrisse, balance, Flavonid, Histamin, neofresh, neolefrin, neoquimica Vitamins, Neosorum, and Torsilax brands; and over-the-counter drugs under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Hypera SA data using free add-ons & libraries
Get Hypera SA Fundamental Data
Hypera SA Fundamental data includes:
- Net Revenue: 7 778 M
- EBITDA: 2 329 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hypera SA News

Hypera SA (HYPMY) Q3 2024 Earnings Call Highlights: Strong Sellout Growth and Strategic ...
Sellout Growth: 11% in Q3 2024, driven by normalization of demand for flu, respiratory pain, and fever products. Gross Margin: Maintained close to 60% despite lower revenue. Marketing Expenses: Increa...


Hypera SA (HYPMY) Q2 2024 Earnings Call Highlights: Strong Cash Flow and Strategic R&D ...
Net Revenue: BRL2.2 billion for the second quarter. Operational Cash Flow: BRL624 million, representing 80% of EBITDA conversion into cash generation. EBITDA Margin: 34.5% for the quarter. Net Income:...

HYPMY Stock Earnings: Hypera Reported Results for Q2 2024
Hypera just reported results for the second quarter of 2024.

HYPMY Stock Earnings: Hypera Reported Results for Q1 2024
Hypera just reported results for the first quarter of 2024.
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.